Catachem — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Catachem is a long-established, private player in the diagnostics sector, specializing in veterinary and research-use-only clinical chemistry reagents. The company leverages over 40 years of manufacturing expertise to provide accurate, stable, and cost-effective testing solutions, complemented by top-tier technical support. Its strategic evolution includes the 2010 acquisition of Bacton Assay Systems to add immunoassay capabilities and a growing focus on CDMO/lyophilization services. With plans for new regulatory submissions in 2024, Catachem is positioned to solidify its role in niche diagnostic markets.

Diagnostics

Technology Platform

Formulation and lyophilization of clinical chemistry and immuno-turbidimetric reagents for automated analyzers.

Opportunities

Growth in the pet care and veterinary diagnostics market provides a strong tailwind for its core reagent business.

The expansion of its CDMO and custom lyophilization services taps into the booming biopharma outsourcing trend, offering a high-value, scalable revenue stream.

Risk Factors

Intense competition from larger, well-capitalized diagnostic companies in both veterinary and human segments could pressure market share and pricing.

Regulatory delays or failures in the planned 2024 FDA/IVDR submissions could hinder expansion into the regulated human diagnostics market.

Competitive Landscape

Catachem competes in veterinary diagnostics against giants like IDEXX Laboratories and Zoetis, relying on specialization and service. In the broader reagent and CDMO space, it faces competition from global diagnostic firms (Roche, Siemens) and larger contract manufacturers, differentiating through its focused expertise in lyophilization and mid-sized flexibility.

More companies in Diagnostics & Precision Medicine →More companies in United States →